Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis

Annals of Hepatology

Zhenying Wu¹  Lu Guo²  Kun He³  Jiali Chen⁴  Ke Su⁴  Yunwei Han⁴ 

[1]Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China

[2]Corresponding author.

[3]Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China

[4]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China

关键词: External radiotherapy;    Hepatoma;    Hepatocellular carcinoma;    Sorafenib;    Meta-analysis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction and Objectives: Both external radiotherapy and sorafenib are promising treatments for hepatocellular carcinoma (HCC). Nevertheless, the combined treatment of external radiotherapy and sorafenib has not been widely applied clinically due to potentially adverse effects. This meta-analysis aimed to evaluate the clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of HCC. Methods: Pubmed, MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were searched. The primary and secondary observation endpoints were the end of survival and incidence of adverse events, respectively. 11 studies involving 664 patients were included in this meta-analysis. Results: The results demonstrated that median overall survival (mOS) and median progression-free survival (mPFS) of the external radiotherapy combined with sorafenib (RS) group were 19.45 months and 8.20 months. The one- and two-year survival rates were 0.65 (95%CI: 0.55–0.76) and 0.40 (95%CI: 0.24–0.56). The incidence of adverse events was 0.34 (95%CI: 0.25–0.44). Conclusions: The findings demonstrated that the survival of the RS group was significantly improved and few severe adverse events were observed. Hence, it can be concluded that external radiotherapy combined with sorafenib is a safe, effective, and promising therapeutic option for HCC.

【 授权许可】

Unknown